Medical devices, healthcare technology and the business of care
PMA approval · P010029

EUFLEXXA (1% SODIUM HYALURONATE)

Ferring Pharmaceuticals, Inc. · Decision date Dec 3, 2004

MEDTECHLEDGER EXPLANATIONP010029

What did the FDA approve?

FDA approved PMA P010029 on December 3, 2004, for EUFLEXXA (1% sodium hyaluronate), submitted by Ferring Pharmaceuticals, Inc. The device is classified under product code MOZ as hyaluronic acid for intraarticular use in the orthopedic specialty. The approval statement identifies the indication as treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics such as acetaminophen.

The record contains no supplement type or supplement reason, so this entry reflects the original PMA decision rather than a change to a previously approved system. The source statement reports the intended purpose but does not provide independent proof of safety or clinical effectiveness. No clinical trial data, comparative efficacy findings, or post-approval requirements appear in the supplied fields.

FDA approval order statement

APPROVAL FOR NUFLEXXA (1% SODIUM HYALURONATE). THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Dec 3, 2004

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010029
Regulatory pathway
Premarket approval application
Product code
MOZ
Decision code
APPR
Decision date
Dec 3, 2004
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P010029 received

    Application receipt date recorded by FDA.

  2. P010029 · FDA decision

    APPR

  3. P010029/S043 · Related supplement

    EUFLEXXA (1% sodium hyaluronate)

Timeline entries are records held by MedtechLedger for P010029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010029

Product / regulatory recordCompanyPathwayDecision dateSource
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA
GEL-ONEP080020
Seikagaku Corp.PMA approvalMar 22, 2011FDA
SUPARTZ FXP980044
Seikagaku Corp.PMA approvalJan 24, 2001FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ferring Pharmaceuticals, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Interpace Pkwy., Parsippany, NJ, 07054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records